From October 18 to 19, 2021, Evergreen Therapeutics Co., Ltd. held its first offline meeting at the US headquarters since the outbreak in Bethesda, Maryland. Dr. Tom Du, Chairman of the Board, Dr. Xin Du, Chief Executive Officer, Dr. Charles Lee, Chief Medical Officer, COO Kevin Wang, CFO Julia Lu, the Clinical and Preclinical Division Director, senior consultant of the company and former senior FDA officer Dr. Florence Houn and other members of Evergreen's consulting team attended the meeting.

Figure 1: The first meeting of Evergreen's team, department directors and consultants

Under the chairmanship of Dr. Xin Du, the meeting reviewed the excellent achievements of Evergreen Therapeutics in the past two years; Dr. Charles Lee, Chief Medical Officer, made a systematic and detailed introduction to the company's pipeline layout and R&D strategy, and the directors of each department, including clinical/preclinical, business cooperation and intellectual property, CMC and legal declaration departments, made detailed work reports successively. In addition, Dr. Florence Houn, a former FDA review officer, also provided important comments on the pipeline of EG-009 for COVID-19 treatment and suggested directions for the upcoming Phase II and III clinical trials. At the same time, each project leader provided comprehensive briefings on the progress of existing projects and product pipelines, as well as cross-functional discussions and information integration with Evergreen's consulting team.

Photo 2: Some members of eglin's American team

Evergreen has obtained 15 patents and 46 patent cases in two years, and its R&D pipeline has been expanded to 13, making significant progress. Several pipelines have entered or will enter Phase I, II clinical trials in the United States, India and some Latin American countries. All the achievements are due to the hard work and dedication of every member of Evergreen's Medical team. We firmly believe that Evergreen will go further and better, and truly realize the vision of "focusing on clinical needs and achieving medical value".